Frontiers Case report: Short-term eculizumab use in atypical HUS

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies - ScienceDirect

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era

PDF) Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort

Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy

Spotlight on aHUS Research - July 2021 - aHUS Alliance Action

Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era

PDF) The use of eculizumab in gemcitabine induced thrombotic microangiopathy

Frontiers Publishing Partnerships First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient

Pregnancy associated atypical hemolytic uremic syndrome presenting with preeclampsia with HELLP syndrome and following treatment with Eculizumab